The Development and Validation of MRI-AI-based Predictive Models for CsPCa

Launched by PEKING UNIVERSITY FIRST HOSPITAL · Feb 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of advanced artificial intelligence (AI) technology to help predict the presence of clinically significant prostate cancer (csPCa) in men. Researchers are looking at data from patients who have had a prostate MRI and a biopsy to see how well AI can analyze MRI images and other clinical information, like age and PSA levels (a blood test that helps detect prostate issues). The goal is to develop and validate predictive models that can better identify men who might have more serious forms of prostate cancer.

To be eligible for this study, participants must be males who have had an MRI and a biopsy within three months of each other and have complete medical records available. However, those with a PSA level below 50 ng/ml or who have received any previous cancer treatments will not be included. If you join the study, you’ll provide information about your health, undergo MRI scans, and have your biopsy performed as usual, with the added benefit of contributing to research that may improve future prostate cancer detection methods.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • The interval between prostate MRI and biopsy within 3 months
• • Integrity of related data
• Exclusion Criteria:
• • PSA less than 50ng/ml
• • Any treatment for PCa prior to either MRI or biopsy, including radical prostatectomy, radiotherapy, chemotherapy, and endocrine therapy
• • Previous history of surgical treatment or 5α-reductase inhibitor therapy for benign prostatic hyperplasia
• • Subjects undergoing MRI with an indwelling urinary catheter or suprapubic catheter
• • Inadequate quality of MRI images